Adjuvants in influenza vaccines

被引：53

作者：

Tetsutani, Kohhei

Ishii, Ken J.

机构：

[1] Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation

来源：

VACCINE | 2012年 / 30卷 / 52期

关键词：

Vaccine adjuvant; Influenza vaccine; H5N1; VACCINE; ALUMINUM-HYDROXIDE; A/H5N1; SAFETY; IMMUNOGENICITY; VIRUS; RESPONSES; CHILDREN; EFFICACY; ADULTS;

D O I：

10.1016/j.vaccine.2012.10.007

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The effectiveness of influenza vaccines is still controversial, and the role of adjuvants in such vaccines is briefly reviewed in this paper. Inactivated whole virus vaccines may include components that function as adjuvants, meaning that additive adjuvants are often not required. MF59 and AS03 showed higher adjuvanticity than aluminum salts in several clinical studies. Recent research has suggested that immune cell recruitment is the main mechanism underlying adjuvant actions in general, and that aluminum salts induce this recruitment via inflammation at the injected site. The aspect of how oil-based adjuvants, such as MF59 and AS03, recruit immune cells remains to be clarified. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：7658 / 7661

页数：4

共 39 条

[1] [Anonymous], CPMPBWP21496 EUR AG
[2] Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations
Atmar, Robert L.
Keitel, Wendy A.
Patel, Shital M.
Katz, Jacqueline M.
She, Dewei
El Sahly, Hana
Pompey, Justine
Cate, Thomas R.
Couch, Robert B.
[J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (09) : 1135 - 1142
[3] Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults
Brady, Rebecca C.
Treanor, John J.
Atmar, Robert L.
Keitel, Wendy A.
Edelman, Robert
Chen, Wilbur H.
Winokur, Patricia
Belshe, Robert
Graham, Irene L.
Noah, Diana Lee
Guo, Kuo
Hill, Heather
[J]. VACCINE, 2009, 27 (37) : 5091 - 5095
[4] Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial
Bresson, Jean-Louis
Perronne, Christian
Launay, Odile
Gerdil, Catherine
Saville, Melanie
Wood, John
Hoeschler, Katja
Zambon, Maria C.
[J]. LANCET, 2006, 367 (9523) : 1657 - 1664
[5] Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes
Calabro, Samuele
Tortoli, Marco
Baudner, Barbara C.
Pacitto, Alessandra
Cortese, Mario
O'Hagan, Derek T.
De Gregorio, Ennio
Seubert, Anja
Wack, Andreas
[J]. VACCINE, 2011, 29 (09) : 1812 - 1823
[6] Live Attenuated Influenza Vaccine (FluMist®; Fluenz™) A Review of its Use in the Prevention of Seasonal Influenza in Children and Adults
Carter, Natalie J.
Curran, Monique P.
[J]. DRUGS, 2011, 71 (12) : 1591 - 1622
[7] Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans
Caskey, Marina
Lefebvre, Francois
Filali-Mouhim, Abdelali
Cameron, Mark J.
Goulet, Jean-Philippe
Haddad, Elias K.
Breton, Gaelle
Trumpfheller, Christine
Pollak, Sarah
Shimeliovich, Irina
Duque-Alarcon, Angela
Pan, Li
Nelkenbaum, Annette
Salazar, Andres M.
Schlesinger, Sarah J.
Steinman, Ralph M.
Sekaly, Rafick P.
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2011, 208 (12) : 2357 - 2366
[8] Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine.
Clark, Tristan W.
Pareek, Manish
Hoschler, Katja
Dillon, Helen
Nicholson, Karl G.
Groth, Nicola
Stephenson, Iain
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (25) : 2424 - 2435
[9] Toll-like receptor 7 and 8 polymorphisms: associations with functional effects and cellular and antibody responses to measles virus and vaccine
Clifford, Holly D.
Yerkovich, Stephanie T.
Khoo, Siew-Kim
Zhang, Guicheng
Upham, John
Le Souef, Peter N.
Richmond, Peter
Hayden, Catherine M.
[J]. IMMUNOGENETICS, 2012, 64 (03) : 219 - 228
[10] Cox M, PANDEMIC INFLUENZA V

← 1 2 3 4 →